

**NIHR**

Nil

### **The King's Fund**

#### **The rise and decline of the NHS in England 2000–20: How political failure led to the crisis in the NHS and social care**

Former Chief Executive of The King's Fund Chris Ham's analysis focuses on the period since 2010 and the factors that contributed to the decline of the NHS after the progress made in the previous decade. While the current situation can feel overwhelming, the improvements that occurred between 2000 and 2010 show that change is possible where political will exists. The paper proposes what needs to be done to sustain and reform the NHS, with a focus on spending decisions, moderating demand and sharing responsibility with patients and the public, alongside a long-term perspective.

Systematic search: No

April 2023

<https://www.kingsfund.org.uk/publications/rise-and-decline-nhs-in-england-2000-20>

### **Scottish Medicines Consortium (SMC Advice)**

#### **trastuzumab deruxtecan (Enhertu®)**

Accepted for restricted use as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-deruxtecan-enhertu-full-smc2545/>

#### **patiromer sorbitex calcium (Veltassa®)**

Accepted for restricted use for the treatment of hyperkalaemia in adults in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/patiromer-sorbitex-calcium-veltassa-abb-smc2568/>

#### **pembrolizumab (Keytruda®)**

Accepted for use as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-full-smc2526/>

#### **darolutamide (Nubeqa®)**

NOT recommended for use as treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/darolutamide-nubega-mhspc-full-smc2544/>

**casirivimab and imdevimab (Ronapreve®)**

NOT recommended for the treatment of acute COVID-19 infection.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/casirivimab-and-imdevimab-ronapreve-full-smc2553/>

**tocilizumab (RoActemra®)**

Accepted for use for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/tocilizumab-roactemra-full-smc2552/>

**nirmatrelvir and ritonavir (Paxlovid®)**

Accepted for restricted use for the treatment of COVID-19 in adults who do not require supplemental oxygen. Restricted to patients with increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/nirmatrelvir-and-ritonavir-paxlovid-full-smc2557/>

**sotrovimab (Xevudy®)**

Accepted for use for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection and nirmatrelvir and ritonavir is contraindicated or unsuitable.

Systematic search: No

April 2023

<https://www.scottishmedicines.org.uk/medicines-advice/sotrovimab-xevudy-full-smc2555/>

**Scottish Government**

**Cancer prehabilitation survey: findings report**

Summarises the findings from a survey of stakeholders and service providers about cancer rehabilitation and rehabilitation services in Scotland.

Systematic search: No

April 2023

<https://www.gov.scot/publications/cancer-prehabilitation-scotland-report-survey-findings/>

**Pandemic personal protective equipment (PPE) future supply: lessons learned**

Identifies the successes, challenges and lessons to be learned relating to PPE supply during the COVID-19 pandemic.

Systematic search: No

April 2023

<https://www.gov.scot/publications/pandemic-personal-protective-equipment-ppe-future-supply-lessons-learned/>

### **National Review of Eating Disorder Services Implementation Group: final report**

Final report of the National Review of Eating Disorder Services Implementation Group. The Group was established to develop the early approach for taking forward the recommendations from the National Review of Eating Disorder Services.

Systematic search: No

April 2023

<https://www.gov.scot/publications/national-review-eating-disorder-services-implementation-group-final-report/>

### **Experiencing Life Events and Childhood Subjective Wellbeing: A Longitudinal Analysis of Growing Up in Scotland**

Growing Up in Scotland (GUS) is a longitudinal study following the lives of young people. This report presents analysis of several data sweeps of Birth Cohort 1 (BC1) and looks at the impact of some key life events on measures of subjective wellbeing.

Systematic search: No

March 2023

<https://www.gov.scot/publications/experiencing-life-events-childhood-subjective-wellbeing-longitudinal-analysis-growing-up-scotland/>

### **NAIT Adult Neurodevelopmental Pathways report**

In 2021, there was a recognised need to improve experiences and outcomes for autistic adults, adults with ADHD and those with co-occurring neurodevelopmental conditions in Scotland. This report details innovative and new ways of working towards these goals, including future recommendations.

Systematic search: No

March 2023

<https://www.gov.scot/publications/nait-adult-neurodevelopmental-pathways-report/>

### **Time Space Compassion - supporting people experiencing suicidal crisis: stories in practice – vol 1**

This is a collection of practice stories, illustrating the principles and supporting practices of Time Space Compassion - a relationship and person centred approach to improving suicidal crisis support.

Systematic search: No

March 2023

<https://www.gov.scot/publications/time-space-compassion-supporting-people-experiencing-suicidal-crisis-stories-time-space-compassion-practice-volume-1/>

## **SIGN**

### **National clinical guideline for stroke for the UK and Ireland (SIGN 166)**

The guideline for stroke provides authoritative, evidence-based practice guidance to improve the quality of care delivered to every adult who has had a stroke in the United Kingdom and Ireland. The 2023 edition is a partial update of the 2016 edition. Almost 300 recommendations have been updated and cover a number of areas including organisation of services, acute care, rehabilitation and recovery, long term management and secondary prevention.

Systematic search: Yes

April 2023

<https://www.sign.ac.uk/our-guidelines/national-clinical-guideline-for-stroke-for-the-uk-and-ireland/>

### **Pharmacological management of migraine (SIGN 155 – update)**

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache. The guideline was updated in 2022 and 2023 to include new recommendations on CGRP monoclonal antibodies and new safety advice on the use of therapies during pregnancy.

Systematic search: Yes

March 2023

<https://www.sign.ac.uk/our-guidelines/pharmacological-management-of-migraine/>

## **Public Health Scotland**

### **Evaluation of the Scottish Grocers' Federation Healthy Living Programme**

Launched in 2004, the SGF Healthy Living Programme (HLP) is a partnership between the Scottish Government, SGF and the convenience retail sector in Scotland. It acknowledges the role convenience stores can play in supporting individuals and families to make healthier life choices. It aims to improve the accessibility, quality and affordability of healthier food options within local convenience retailers across Scotland, especially those in areas of multiple deprivation, and in doing so, support Scottish retailers to increase sales of healthier foods. While the availability of healthier options has improved, the quality of retailer engagement is variable. The key barrier that the programme has not been able to successfully address is that of affordability. Participating retailers and customers were conscious of the high cost of fresh fruit and vegetables, and this was believed to be limiting engagement with the healthier offering under the HLP.

Systematic search: No

April 2023

<https://www.publichealthscotland.scot/publications/evaluation-of-the-scottish-grocers-federation-healthy-living-programme/evaluation-of-the-scottish-grocers-federation-healthy-living-programme/>

### **Improving access for Gypsy/Travellers to the NHS and health and social care in Scotland**

Two linked publications aim to help Health Boards and Health and Social Care Partnerships improve the health and wellbeing of Gypsy/Traveller communities. "How you can improve the health of Gypsy/Travellers in Scotland" discusses some of the inequalities experienced by Gypsy/Traveller communities. It highlights some practical solutions that Health Boards and Health and Social Care Partnerships can implement to try to improve the health outcomes of Gypsy/Travellers in their area. The second publication "Improving access ..." will support people who are undertaking an equality impact assessment or health inequality impact assessment to consider the likely impacts of policy, strategy or service development on Gypsy/Travellers in Scotland.

Systematic search: No

April 2023

<https://publichealthscotland.scot/publications/improving-access-for-gypsytravellers-to-the-nhs-and-health-and-social-care-in-scotland/improving-access-for-gypsytravellers-to-the-nhs-and-health-and-social-care-in-scotland/>

### **Rapid evidence review on interventions to reduce drug-related harm during transitions of care**

The review found a limited evidence base, most of which covered the USA. Outcomes excluded perceptions of service providers and no studies looked at patient survival or other individual outcome measures. There was some evidence of the effectiveness of in-person and digital methods for establishing trust and contact. Stable housing and employment, practical assistance and funding to address basic needs, can decrease gaps in care and address support needs. Including a variety of these models and having more than one model in operation appears to improve service delivery. However, the unmet needs of the population group are substantial and, in some studies, acted as a barrier to engagement of the intervention being offered.

Systematic search: Limited

April 2023

<https://publichealthscotland.scot/publications/rapid-evidence-review-on-interventions-to-reduce-drug-related-harm-during-transitions-of-care/>

## **NICE – Guidelines**

### **NG191 COVID-19 rapid guideline: managing COVID-19 (Update)**

The section on therapeutics for COVID-19 contains updated recommendations on baricitinib and remdesivir, casirivimab plus imdevimab, nirmatrelvir plus ritonavir, and tocilizumab. The recommendations on neutralising monoclonal antibodies and sarilumab are replaced with recommendations on sotrovimab and tocilizumab

Systematic search: Limited

March 2023

<https://www.nice.org.uk/guidance/ng191>

## **NICE - Technology Appraisal Guidance**

### **TA880 Tezepelumab for treating severe asthma**

Systematic search: Limited

April 2023

<https://www.nice.org.uk/guidance/ta880>

### **TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19**

Systematic search: Limited

March 2023

<https://www.nice.org.uk/guidance/ta878>

## **EPPI Centre**

Nil

## **AHRQ (Agency for Healthcare Research and Quality – USA)**

Nil

## **Health Foundation**

Nil

## **Canadian Agency for drugs and Technologies in Health (CADTH)**

### **Risk of Sexual Transmission of HIV With Antiretroviral Therapy and Variable or Suppressed Viral Load**

The absolute risk of HIV transmission through sexual activity, reported as incidence rates of observed seroconversions across person-years of follow-up, ranged widely across the included studies of sex partners living with HIV with variable (or unreported) viral loads. Two studies included sex partners living with HIV with suppressed viral loads of fewer than 200 copies/mL, reporting no phylogenetically linked seroconversions in either study. Most studies in this report included data from heterosexual serodiscordant sex partners and did not report follow-up viral loads of sex partners living with HIV. The included studies incorporated variable methods, investigated a broad variety of populations and exposures, and demonstrated a wide range of methodological strengths and limitations.

Systematic search: Yes

April 2023

<https://www.cadth.ca/risk-sexual-transmission-hiv-antiretroviral-therapy-and-variable-or-suppressed-viral-load>

### **Occupational Therapy for Mental Health Conditions and Substance Use Disorders**

Occupational therapy interventions may be effective for reducing symptoms of depression and anxiety and improving function and participation with the interventions in adult patients diagnosed with depression and/or anxiety. In patients with schizophrenia, occupational therapy interventions may improve social functioning, cognitive performance, executive function, and motivation; and reduce the duration and rate of rehospitalization. No evidence was found regarding the clinical effectiveness of occupational therapy for the treatment of bipolar disorders, obsessive-compulsive disorder, and post-traumatic stress disorder that met the inclusion criteria for the review. No evidence was found meeting the inclusion criteria about the cost-effectiveness of occupational therapy for the treatment of mental health conditions, as well as the clinical effectiveness and cost-effectiveness of occupational therapy for the treatment of substance use disorders.

Systematic search: Yes

April 2023

<https://www.cadth.ca/occupational-therapy-mental-health-conditions-and-substance-use-disorders>

### **McGill University Health Centre (Canada)**

Nil

### **Health Information & Quality Authority (Ireland) – Health Technology Assessments**

Nil

### **Campbell Collaboration**

Nil

### **Glasgow Centre for Population Health**

Nil

### **NICE FORWARD PLANNING – Publications due MAY 2023**

#### **Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment**

Diagnostic Technology

#### **Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers**

Diagnostic Technology

#### **MRI fusion biopsy in people with suspected prostate cancer**

Diagnostic Technology

#### **Cardiovascular disease: risk assessment and reduction, including lipid modification**

Clinical Guideline

#### **Difelikefalin for treating pruritus in people having haemodialysis**

Technology Appraisal

**Pembrolizumab in combination with platinum-based chemotherapy for treating persistent, recurrent or metastatic cervical cancer]**

Technology Appraisal

**Voclosporin with immunosuppressives for treating lupus nephritis**

Technology Appraisal

**Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies**

Technology Appraisal

**Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma**

Technology Appraisal

**Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer**

Technology Appraisal

**Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy]**

Technology Appraisal

**Risankizumab for previously treated moderately to severely active Crohn's disease**

Technology Appraisal

**Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer**

Technology Appraisal

**Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer**

Technology Appraisal

**Bulevirtide for treating chronic hepatitis D**

Technology Appraisal

**Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia**

Technology Appraisal